Alkahest, with its partner Grifols, is developing lead clinical candidates, GRF6019 and GRF6021, as potential treatments for neurodegenerative diseases including Alzheimer’s disease and Parkinson’s disease with cognitive impairment. Designed to safely replenish regenerative positive chronokines that decrease with age, GRF6019 and GRF6021 are highly selected human plasma fractions that provide enhancement of cognition and motor activity, reduction of inflammation and restoration of neurogenesis.
GRF6019 has completed a Phase 2 trial for the treatment of mild to moderate Alzheimer’s disease. The data from this trial were presented at CTAD 2019. GRF6021 is being investigated in an ongoing placebo-controlled Phase 2 trial for the treatment of Parkinson’s disease with cognitive impairment, supported in part by The Michael J. Fox Foundation (MJFF). GRF6021 is also being studied in a clinical trial investigating postoperative recovery following hip and knee repair.
GRF6019 and GRF6021, proprietary plasma fractions, are developed and manufactured by Grifols. Grifols is one of the world’s largest producers of plasma-derived medicines.
Debbie Wallace, Corporate Controller